Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.

Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.

cls.cnNov 15 11:14 ET

Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.

cls.cnNov 13 08:52 ET

Securing the indication of the world's first long-acting growth hormone ISS globally, is there a solution to the situation of both revenue and net profit decline at Changchun High-tech Industries? | Announcement for quick reading

①On the 5th, changchun high-tech industries announced that its long-acting growth hormone has been approved for ISS indication. In August of this year, this variety was also approved for the growth disorder in girls with gonadal dysgenesis (Turner syndrome); ②In the first three quarters of this year, changchun high-tech industries' performance and profitability both declined. Whether the main products that have been on the market for 10 years can have new sales volume is widely watched.

cls.cnNov 5 09:31 ET

Pharmaceutical business shrinks, livzon pharmaceutical group inc. revenue declines year-on-year in the first three quarters | interpretations

1. In the first three quarters of this year, livzon pharmaceutical group inc.'s revenue decreased by a single-digit percentage compared to the same period last year, while net profit attributable to shareholders maintained positive growth year-on-year; 2. The revenue of the pharmaceutical sector, which contributed the most, declined; 3. Semaglutide has been submitted for marketing approval for the indication of diabetes, and the development of weight loss indication has entered phase III clinical trials.

cls.cnOct 23 09:27 ET

The launch of new medical beauty products contributed to performance, jiangsu wuzhong pharmaceutical development's net profit in the first three quarters increased by more than three times. | Interpretations

① In the first three quarters, jiangsu wuzhong pharmaceutical development's net profit attributable to the parent company increased by 311.54% year-on-year; ② The significant increase in performance during the reporting period of the AestheFill aesthetic facial filler contributed mainly to the company's performance growth; ③ The decline in the pharmaceutical sector business continues to expand.

cls.cnOct 21 07:25 ET

It is expected that relevant national authorities will establish a low-altitude economic regulatory bureau.

①The establishment decision has been approved, and the new bureau is currently in preparation; ② The low-altitude economy set up a dedicated bureau, which can better coordinate resources at all levels to promote industrial development.

cls.cnOct 18 01:13 ET